Genelux (GNLX)

• Market cap: $116M
• 1 day: -0.76%
• 5 days: -4.06%
• 1 month: -0.76%
• 3 months: -37.95%
• 6 months: -35.16%
• Year to date: -42.86%
• 1 year: -29.73%
• 5 years: -57.72%
• 10 years: -57.72%
• Sector: Healthcare
• Industry: Biotechnology

About: Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

Employees: 24